Wells out positive on BioCryst HAE franchise

• Wells Fargo is out with an upbeat note on BioCryst (BCRX +4.6%) following news the company has advanced two new plasma kallikrein inhibitors into preclinicals.
  
• "While the second generation compounds are still at an early preclinical stage, PK profiles of the compounds look promising, suggesting that they could potentially further improve upon '4161's profile (and IP) and help the long-term life cycle management of the company's potential HAE franchise," analyst Brian Abrahams notes.